

Potential Indications for CytoSorb Therapy in ECMO/ECLS Patients:

The following clinical conditions are characterized or aggravated by hyperinflammation, often with deterioration and shock. Cytosorb therapy may therefore be considered in addition to standard of care and treatment of the underlying cause in:

- Cardiogenic shock
- ECPR
- Bridge to VAD surgery
- ARDS with high vasopressor demand
- Post cardiectomy syndrome
- Infective endocarditis
- Septic shock
- *Liver failure (removal of bilirubin)*
- *Rhabdomyolysis (removal of myoglobin)*

Visit <http://literature.cytosorb.com> for an overview of all references

CytoSorbents Europe GmbH

Müggelseedamm 131
12587 Berlin | Germany

T +49 30 65 49 91 45
F +49 30 65 49 91 46
support@cytosorbents.com

CytoSorbents Switzerland GmbH

c/o MGM GmbH
Wielandstrasse 5 | 4153 Reinach BL | Switzerland


T +41 61 713 73 78
F +41 61 713 73 79
support@cytosorbents.com

CytoSorb and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. B1088R02EN2019 © Copyright 2019, CytoSorbents Europe GmbH. All rights reserved.


CytoSorb should only be administered by personnel who have been properly trained in administration of extracorporeal therapies. CytoSorb is not available for commercial sale in USA. This proposal is non-binding. It is based on available data and experience, but has not yet been evaluated in randomized controlled trials. It cannot replace individual therapeutic decisions of the treating physician.

CytoSorb Therapy

Decision support for ECMO/ECLS patients



CytoSorb Therapy - Initiation



CytoSorb Therapy - Continuation

